Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice.

3,3'-Diindolylmethane (DIM) is a naturally occurring indole, which is currently under investigation as a potential chemopreventive agent. The concentrations of DIM in plasma, liver, kidney, lung, heart, and brain tissues were determined following oral administration of two different formulations to mice (250 mg/kg). Mice were sacrificed periodically from 0 to 24 h after administration of either a crystalline or an absorption-enhanced formulation (Bio-Response-DIM; Indolplex) of DIM, and plasma and tissue concentrations were determined by high-performance liquid chromatography (UV detection, 280 nm). A physiologically based pharmacokinetic (PBPK) model was developed to characterize the pharmacokinetic properties of the two different formulations. The final model included parameters reflecting linear first-order absorption, systemic clearance, and distributional clearance in the remainder compartment, which were considered independent of formulation. All pharmacokinetic profiles from the two formulations were fitted simultaneously to estimate unknown model parameters. Plasma and tissue concentration-time profiles exhibited a rapid rise to peak values at 0.5 to 1 h, followed by a polyexponential decline with an extended terminal phase. These profiles were well described by the final model and unknown parameters were estimated with relatively low coefficients of variation. Relative drug exposure and absorption parameters suggest that BioResponse-DIM exhibited approximately 50% higher bioavailability than the crystalline formulation. Clearance of DIM was estimated as 7.18 ml/h. This is the first study to characterize the pharmacokinetics of DIM in mice, and the established PBPK model should prove useful in the design and analysis of future preclinical studies aimed at evaluating the in vivo pharmacological effects of DIM.

[1]  Michnovicz Jj,et al.  Altered estrogen metabolism and excretion in humans following consumption of indole‐3‐carbinol , 1991 .

[2]  G. Firestone,et al.  Cytostatic effects of 3,3'-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. , 2001, Carcinogenesis.

[3]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[4]  A. Okey,et al.  Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. , 1993, Biochemical pharmacology.

[5]  V. Steele,et al.  Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. , 1995, Anticancer research.

[6]  H. Bradlow,et al.  Quantitative Determination of 3,3?-Diindolylmethane inUrine of Individuals Receiving Indole-3-Carbinol , 2001, Nutrition and cancer.

[7]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[8]  J. Hayes,et al.  Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. , 2001, Cancer research.

[9]  L. Bjeldanes,et al.  Organ-selective induction of cytochrome P-450-dependent activities by indole-3-carbinol-derived products: influence on covalent binding of benzo[a]pyrene to hepatic and pulmonary DNA in the rat. , 1992, Chemico-biological interactions.

[10]  D. Williams,et al.  The anticarcinogen 3,3'-diindolylmethane is an inhibitor of cytochrome P-450. , 1995, Journal of biochemical toxicology.

[11]  David E. Williams,et al.  Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in sprague-dawley rats. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  G. Firestone,et al.  3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. , 2002, Carcinogenesis.

[13]  E. J. Mayeaux,et al.  Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. , 2000, Gynecologic oncology.

[14]  L. Bjeldanes,et al.  Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. , 1987, Journal of toxicology and environmental health.

[15]  L. Aarons,et al.  Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  S. Safe,et al.  Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. , 1998, Carcinogenesis.

[17]  J. Hendricks,et al.  In vivo disposition of the natural anti-carcinogen indole-3-carbinol after po administration to rainbow trout. , 1989, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[18]  M. Osborne,et al.  Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. , 1991, Carcinogenesis.

[19]  G Rennert,et al.  3,3'-Diindolylmethane induces apoptosis in human cancer cells. , 1996, Biochemical and biophysical research communications.

[20]  H. Bradlow,et al.  Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. , 1991, Nutrition and Cancer.

[21]  J. Noordhoek,et al.  Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. , 1991, Chemico-biological interactions.

[22]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[23]  F. Fares,et al.  Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[24]  D. Miller,et al.  Long-term responses of women to indole-3-carbinol or a high fiber diet. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  D. Judah,et al.  Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver--predicting the outcome using early biomarkers. , 1998, Carcinogenesis.

[26]  L. Bjeldanes,et al.  Oligomerization of indole-3-carbinol in aqueous acid. , 1992, Chemical research in toxicology.

[27]  D. Williams,et al.  Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[28]  T. Carter,et al.  Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. , 2001, The Journal of nutrition.

[29]  H. Bradlow,et al.  Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. , 1999, Anticancer research.

[30]  M. Anderton,et al.  Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  L. Wattenberg,et al.  Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. , 1978, Cancer research.

[32]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.